Myriad Genetics (MYGN) has disclosed its preliminary financial results for the fourth quarter and full year ending December 31, 2024, while also offering guidance for the 2025 fiscal year. The company forecasts a fourth quarter GAAP loss per share ranging from $0.72 to $0.62, with an adjusted profit per share expected between $0.03 and $0.04. The GAAP net loss for the fourth quarter is estimated to be between $65.7 million and $56.8 million. Revenue for the quarter is projected to rise by approximately 6% to 7%, totaling between $209 million and $211 million.
For the full year of 2024, the company anticipates a GAAP loss ranging from $151 million to $142 million. The GAAP loss per share is expected to lie between $1.66 and $1.56, while the adjusted profit per share is projected to be between $0.14 and $0.15. Total revenues for the year are anticipated to reach between $836 million and $838 million, marking an approximate 11% increase compared to 2023.
Looking ahead to 2025, Myriad Genetics projects adjusted earnings per share ranging from $0.07 to $0.11, with revenues expected to be between $840 million and $860 million.
The material has been provided by InstaForex Company -
www.instaforex.com
